PDCD1 and Hodgkins lymphoma: Whether PD-1/PD-L1 antibodies can safely be administered after allo-HSCT to prevent disease relapse in high-risk patients warrants further research in larger groups of patients; early reports in patients with Hodgkin lymphoma were not encouraging [35, 39].